Follow
laura esserman
laura esserman
Professor of Surgery and Radiology, University of California, San Francisco
Verified email at ucsf.edu
Title
Cited by
Cited by
Year
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
K Chin, S DeVries, J Fridlyand, PT Spellman, R Roydasgupta, WL Kuo, ...
Cancer cell 10 (6), 529-541, 2006
14102006
Whole-genome analysis informs breast cancer response to aromatase inhibition
MJ Ellis, LI Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ...
Nature 486 (7403), 353-360, 2012
11022012
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A …
JS Vaidya, F Wenz, M Bulsara, JS Tobias, DJ Joseph, M Keshtgar, ...
The Lancet 383 (9917), 603-613, 2014
8492014
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial
JS Vaidya, DJ Joseph, JS Tobias, M Bulsara, F Wenz, C Saunders, ...
The Lancet 376 (9735), 91-102, 2010
8322010
Rethinking screening for breast cancer and prostate cancer
L Esserman, Y Shieh, I Thompson
Jama 302 (15), 1685-1692, 2009
6592009
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
JL Khatcheressian, P Hurley, E Bantug, LJ Esserman, E Grunfeld, ...
6232012
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer
C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ...
Jama 305 (18), 1873-1881, 2011
5752011
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer …
MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat, JS Parker, J Luo, ...
Journal of Clinical Oncology 29 (17), 2342, 2011
5732011
Overdiagnosis and overtreatment in cancer: an opportunity for improvement
LJ Esserman, IM Thompson, B Reid
Jama 310 (8), 797-798, 2013
5672013
Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging
L Esserman, N Hylton, L Yassa, J Barclay, S Frankel, E Sickles
Journal of clinical oncology 17 (1), 110-110, 1999
5001999
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
4872016
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
LJ Esserman, IM Thompson, B Reid, P Nelson, DF Ransohoff, HG Welch, ...
The lancet oncology 15 (6), e234-e242, 2014
4842014
Leukocyte composition of human breast cancer
B Ruffell, A Au, HS Rugo, LJ Esserman, ES Hwang, LM Coussens
Proceedings of the National Academy of Sciences 109 (8), 2796-2801, 2012
4692012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
LJ Esserman, DA Berry, A DeMichele, L Carey, SE Davis, M Buxton, ...
Journal of Clinical Oncology 30 (26), 3242, 2012
4342012
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL
NM Hylton, JD Blume, WK Bernreuter, ED Pisano, MA Rosen, EA Morris, ...
Radiology 263 (3), 663, 2012
4302012
Breast cancer growth prevention by statins
MJ Campbell, LJ Esserman, Y Zhou, M Shoemaker, M Lobo, E Borman, ...
Cancer research 66 (17), 8707-8714, 2006
3962006
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy
SC Partridge, JE Gibbs, Y Lu, LJ Esserman, D Sudilovsky, NM Hylton
American Journal of Roentgenology 179 (5), 1193-1199, 2002
3912002
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ...
Breast cancer research and treatment 132 (3), 1049-1062, 2012
3442012
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
D Horiuchi, L Kusdra, NE Huskey, S Chandriani, ME Lenburg, ...
Journal of Experimental Medicine 209 (4), 679-696, 2012
3302012
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer
WC Dooley, BM Ljung, U Veronesi, M Cazzaniga, RM Elledge, ...
Journal of the national cancer institute 93 (21), 1624-1632, 2001
3092001
The system can't perform the operation now. Try again later.
Articles 1–20